• Home
  • R&D

R&D

OliX Pipeline

  • Pipeline
  • OLX101A
  • OLX201A
  • OLX301A
  • OLX301D

Age-Related Macular Degeneration (AMD)

Occurs when the small central portion of the retina, known as the macula, deteriorates

The leading cause of severe vision loss in people over age 60 in developed countries

Two types: wet AMD (10%) and dry AMD (90%)

Market Potential

Leading cause of vision loss globally; no. 1 disease for vision loss in developed countries

Steady increase of AMD patients globally: 200 million patients in 2020, 3 million patients expected in 2040

AMD patients in the US estimated to be 1.75 million in 2014 (source : All about vision, Understanding AMD 2014)

The global AMD market size has been projected to reach $18.7B by 2028 (Source: GlobalData 2020)

Development Status

Animal efficacy test currently underway at University of Virginia School of Medicine (Collaboration with Dr. J. Ambati, Department of Ophthalmology)

Outstanding efficacy identified from animal models with dry macular degeneration

License and Collaboration Agreement with Théa Open Innovation (Territory: EU, MEA, Africa, 2019.03.15)

Expanded License and Collaboration agreement with Théa Open Innovation (Territory: Worldwide excl. Asia-Pacific)

Preclinical toxicology studies with Charles River Laboratories